Pharmosa Biopharm Inc 2025 Annual Report with Sustainability Disclosures
Company: Pharmosa Biopharm Inc
Sector: Manufacturing
Country: Taiwan
Year: 2025
Type: Annual Report with Sustainability Disclosures
Pages: 165
The report describes 2025 as a year of continued investment in Pharmosa Biopharm's drug-device pipeline, with operating revenue of NT$67,268 thousand. L606 advanced global clinical-trial supply and Phase III development, while L608 achieved important regulatory and development milestones, including European Orphan Drug Designation and submission of its U.S. Phase II IND. The company also established a Sustainability Promotion Task Force, with sustainable-development oversight assigned to the board of directors.
Reporting standards, commitments and assurance details are available with a free account.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.